Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1773

1.

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.

Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.

Arthritis Rheum. 2008 Aug;58(8):2257-67. doi: 10.1002/art.23667.

PMID:
18668547
[PubMed - indexed for MEDLINE]
Free Article
2.
3.

High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.

Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F.

J Rheumatol. 2002 Mar;29(3):454-61.

PMID:
11908556
[PubMed - indexed for MEDLINE]
4.

Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.

Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.

J Rheumatol. 2006 Mar;33(3):497-500.

PMID:
16511906
[PubMed - indexed for MEDLINE]
5.

Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.

Park MC, Chung SJ, Park YB, Lee SK.

Scand J Rheumatol. 2008 May-Jun;37(3):173-8. doi: 10.1080/03009740801898608. Erratum in: Scand J Rheumatol. 2008 Nov-Dec;37(6):492. Jung, SJ [corrected to Chung, SJ].

PMID:
18465450
[PubMed - indexed for MEDLINE]
6.

Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.

Takasugi K, Yamamura M, Iwahashi M, Otsuka F, Yamana J, Sunahori K, Kawashima M, Yamada M, Makino H.

Arthritis Res Ther. 2006;8(4):R126.

PMID:
16859503
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis.

Valle Y, Ledezma-Lozano IY, Torres-Carrillo N, Padilla-Gutiérrez JR, Navarro-Hernández RE, Vázquez-Del Mercado M, Palafox-Sánchez CA, Armendáriz-Borunda J, Muñoz-Valle JF.

Scand J Rheumatol. 2009;38(5):332-5. doi: 10.1080/03009740902865456.

PMID:
19579138
[PubMed - indexed for MEDLINE]
9.

Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?

El Miedany Y, Youssef SS, El Gaafary M.

J Rheumatol. 2006 Mar;33(3):490-7.

PMID:
16511918
[PubMed - indexed for MEDLINE]
10.

Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.

Macías I, García-Pérez S, Ruiz-Tudela M, Medina F, Chozas N, Girón-González JA.

J Rheumatol. 2005 Nov;32(11):2102-8.

PMID:
16265686
[PubMed - indexed for MEDLINE]
11.

Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.

Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME.

J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.

PMID:
17696278
[PubMed - indexed for MEDLINE]
12.

Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint.

Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH.

Arthritis Rheum. 2011 May;63(5):1265-73. doi: 10.1002/art.30273.

PMID:
21305530
[PubMed - indexed for MEDLINE]
Free Article
13.

Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction.

Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, Weedon H, Milliken ST, Tak PP, Smith MD, Breit SN.

Arthritis Rheum. 2007 Mar;56(3):753-64.

PMID:
17328047
[PubMed - indexed for MEDLINE]
Free Article
14.

Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis.

Gerber LH, Furst G, Yarboro C, el-Gabalawy H.

Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S65-70.

PMID:
14969053
[PubMed - indexed for MEDLINE]
15.
16.

Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.

Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P.

J Rheumatol. 2009 Apr;36(4):724-30. doi: 10.3899/jrheum.080626. Epub 2009 Feb 27.

PMID:
19273452
[PubMed - indexed for MEDLINE]
17.

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.

Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M.

J Autoimmun. 2008 Sep;31(2):175-9. doi: 10.1016/j.jaut.2008.07.002. Epub 2008 Aug 15.

PMID:
18707846
[PubMed - indexed for MEDLINE]
18.

CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis.

Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, Ueno A, Ohmoto Y, Makino H.

Arthritis Rheum. 2002 Oct;46(10):2578-86.

PMID:
12384915
[PubMed - indexed for MEDLINE]
Free Article
20.

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.

Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.

Rheumatology (Oxford). 2007 Mar;46(3):446-53. Epub 2006 Aug 9.

PMID:
16899502
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk